The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.
Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.
More top news
Awarded the Victoria Cross for rescuing colleagues from the Somme, a Northern Irish soldier has been honoured with a statue in his town.
China has become Africa's biggest trading partner - but amid accusations of exploitation, all is not well in this remarkable partnership.
A newborn baby girl has been killed by dogs after they attacked her while she was lying on a sofa.